Discontinuation report ULTOMIRIS
| Report ID | 264440 |
| Drug Identification Number | 02491559 |
| Brand name | ULTOMIRIS |
| Common or Proper name | Ravulizumab for injection |
| Company Name | ALEXION PHARMA GMBH |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | RAVULIZUMAB |
| Strength(s) | 10MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS |
| Packaging size | 30 mL |
| ATC code | L04AJ |
| ATC description | |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2025-08-31 |
| Actual discontinuation date | 2025-08-27 |
| Remaining supply date | 2025-07-31 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | Alexion offers Ultomiris100mg/ml supply in two vial size formulations of 3ml and 11ml total volume size. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | NEUHOFSTRASSE 34 BAAR, -- SWITZERLAND 6340 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v9 | 2025-09-10 | French | Compare |
| v8 | 2025-09-10 | English | Compare |
| v7 | 2025-08-06 | French | Compare |
| v6 | 2025-08-06 | English | Compare |
| v5 | 2025-08-06 | French | Compare |
| v4 | 2025-08-06 | English | Compare |
| v3 | 2025-08-06 | French | Compare |
| v2 | 2025-08-06 | English | Compare |
| v1 | 2025-08-06 | English | Compare |
Showing 1 to 9 of 9